A specialized gene editing system designed by scientists at the Lewis Katz School of Medicine at Temple University is paving the way to an eventual cure for patients infected with HIV, the virus that causes AIDS. In a study published online this month in the Nature journal, Scientific Reports, the researchers show that they can both effectively and safely eliminate the virus from the DNA of human cells grown in culture.
According to senior investigator on the new study, Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, Director of the Center for Neurovirology, and Director of the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), “Antiretroviral drugs are very good at controlling HIV infection. But patients on antiretroviral therapy who stop taking the drugs suffer a rapid rebound in HIV replication.” The presence of numerous copies of HIV weakens the immune system and eventually causes acquired immune deficiency syndrome, or AIDS.
Curing HIV/AIDS – which has claimed the lives of more than 25 million people since it was first discovered in the 1980s – is the ultimate goal in HIV research. But eliminating the virus after it has become integrated into CD4+ T-cells, the cells primarily infected with HIV, has proven difficult. Recent attempts have focused on intentionally reactivating HIV, aiming to stimulate a robust immune response capable of eradicating the virus from infected cells. However, to date, none of these “shock and kill” approaches has been successful.
Dr. Khalili and colleagues decided to try a different approach, specifically targeting HIV-1 proviral DNA (the integrated viral genome) using uniquely tailored gene editing technology. Their system includes a guide RNA that specifically locates HIV-1 DNA in the T-cell genome, and a nuclease enzyme, which cuts the strands of T-cell DNA. Once the nuclease has edited out the HIV-1 DNA sequence, the loose ends of the genome are reunited by the cell’s own DNA repair machinery.
In previous work, Dr. Khalili’s team had demonstrated the ability of their technology to snip out HIV-1 DNA from human cell lines. In their latest study, however, they concentrated on latently and productively infected CD4+ T cells to show not only that the technology eliminates the virus from cells but also that its persistent presence in HIV-1-eradicated cells actually protects them against reinfection. More importantly, they carried their work over to ex vivo experiments, in which T-cells from patients infected with HIV were grown in cell culture, showing that treatment with the gene editing system can suppress viral replication and dramatically reduce viral load in patient cells.
In another major component of the study, Dr. Khalili’s team addressed questions about off-target effects and toxicity. Using an approach known as ultra-deep whole-genome sequencing, which is considered the gold standard for genomic assessment, the researchers analyzed the genomes of HIV-1-eradicated cells for mutations in genes outside the region targeted by the guide RNA. Their analyses ruled out off-target effects on genes, including potential collateral effects on cellular gene expression. Studies of cell viability and proliferation showed that HIV-1-eradicated cells were growing and functioning normally.
“The findings are important on multiple levels,” Dr. Khalili said. “They demonstrate the effectiveness of our gene editing system in eliminating HIV from the DNA of CD4 T-cells and, by introducing mutations into the viral genome, permanently inactivating its replication. Further, they show that the system can protect cells from reinfection and that the technology is safe for the cells, with no toxic effects.”
“These experiments had not been performed previously to this extent,” he added. “But the questions they address are critical, and the results allow us to move ahead with this technology.”
Learn more: Scientists at Lewis Katz School of Medicine at Temple University Eliminate HIV-1 from Genome of Human T-Cells
The Latest on: HIV/AIDS
[google_news title=”” keyword=”HIV/AIDS” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: HIV/AIDS
- A&E testing scheme finds thousands of people with HIV and hepatitison June 7, 2023 at 7:34 am
A £20m NHS pilot scheme in A&E departments has helped diagnose thousands of people with HIV and hepatitis. The pilot, which has been running since April 2022 in 33 hospital emergency departments ...
- Now is not the time to stop fighting AIDS (Opinion)on June 7, 2023 at 6:01 am
Bush Institute, UNAIDS, Merck and Roche in a public-private partnership called Go Further, which aims to end AIDS and cervical cancer in sub-Saharan Africa within a generation. Women living with HIV ...
- Transgender HIV/AIDS patients to be treated indiscriminately: Sindh High Courton June 7, 2023 at 4:00 am
KARACHI: The Sindh High Court has ordered the administration of the Civil Hospital to start the treatment of transgender HIV/AIDS patients today.The order was issued after the hearing of a ...
- How the ‘Magna Carta of AIDS activism’ sparked a revolutionon June 7, 2023 at 4:00 am
AIDS hysteria was sweeping the country. This is the story of how a Denver conference empowered a generation—and helped shape a new era of advocacy.
- LGBTQ celebs unleash their inner Elton John to fight HIVon June 6, 2023 at 2:00 pm
Queer Eye’s Antoni Porowski, trans actress Michaela Jae Rodriguez, pansexual musician Jojo Siwa, and tons of other celebrities are busting out the feather boas, rhinestones, and over-the-top glasses ...
- Elton John Hopes To End HIV/AIDS By 2030 As He Launches $125 Million Rocket Fundon June 6, 2023 at 11:15 am
Elton John AIDS Foundation, has launched the Rocket Fund, a $125 million initiative aimed at combating the rising rates of HIV infections.
- Women With HIV on Medicaid Have Higher Prevalence of Cervical, Anal Cancerson June 6, 2023 at 8:22 am
Among women on Medicaid, the prevalence of Kaposi sarcoma—a cancer commonly associated with HIV—was 82 times higher in women with HIV compared with women without HIV.
- Breaking the cycle of HIV/AIDS: Charity ride from Bay Area brings in $11.7M for the causeon June 6, 2023 at 3:00 am
A week-long bike ride from San Francisco to Los Angeles raised $11.7 million for San Francisco and Los Angeles HIV/AIDS organizations, organizers of the event announced this week. On Sunday morning, ...
- ‘Our Story’ returns after 20 years as sign of hope in fight against HIVon June 6, 2023 at 2:10 am
In a series of vignettes, “Our Story” depicts a community coming together through encouraging personal stories about living with HIV.
- SF nonprofit says HIV/AIDS services will be cut at end of month without fundingon June 5, 2023 at 11:32 pm
AGUILAS has provided HIV/AIDS health services for some of San Francisco's most vulnerable. With the program gone, the nonprofit worries patients will simply fall out of system and not get the critical ...
via Bing News